Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

NCT00906698 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BIBW 2992 low (20mg) dosage
DRUG: BIBW 2992 medium (40mg) dosage
DRUG: BIBW 2992 high (50mg) dosage
DRUG: Vinorelbine per os 60 mg/m²
DRUG: Vinorelbine per os 80 mg/m²
DRUG: Vinorelbine i.v. 25 mg/m²

Sponsor

Boehringer Ingelheim